Who are AT-527 and Probenecid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/at-527-and-probenecid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AT-527 and Probenecid — Competitive Intelligence Brief

AT-527 and Probenecid (AT-527 and Probenecid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral, Uricosuric agent. Area: Infectious Disease.

phase 1 Antiviral, Uricosuric agent SARS-CoV-2 RNA-dependent RNA polymerase, Uric acid transporter Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

AT-527 and Probenecid (AT-527 and Probenecid) — Atea Pharmaceuticals, Inc.. AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AT-527 and Probenecid TARGET	AT-527 and Probenecid	Atea Pharmaceuticals, Inc.	phase 1	Antiviral, Uricosuric agent	SARS-CoV-2 RNA-dependent RNA polymerase, Uric acid transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral, Uricosuric agent class)

Atea Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AT-527 and Probenecid — Competitive Intelligence Brief. https://druglandscape.com/ci/at-527-and-probenecid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab